Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis

BACKGROUND: Summarized data of cardiovascular outcomes trials (CVOTs) of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have shown a reduction in major adverse cardiovascular event (MACE), whether these benefits are extended in certain ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Diallo, Alhassane, Carlos-Bolumbu, Miguel, Galtier, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574412/
https://www.ncbi.nlm.nih.gov/pubmed/36263397
http://dx.doi.org/10.1016/j.eclinm.2022.101697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574412/
https://www.ncbi.nlm.nih.gov/pubmed/36263397
http://dx.doi.org/10.1016/j.eclinm.2022.101697

Ejemplares similares